Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting : Episode 9
Opinion
Video
FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC
Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer.
EP: 1.Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting
EP: 2.Selecting Optimal 3L Colorectal Cancer Treatment
EP: 3.Patient Case 1: 46-Year-Old Woman with Prior Hx of MSS pT4aN1b Rectosigmoid Colon Adenocarcinoma s/p Prior Treatment
EP: 4.General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab
EP: 5.Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC
EP: 6.Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer
EP: 7.Treatment Considerations With Regorafenib in Colorectal Cancer
EP: 8.Patient Case 3: A 57-Year-Old Man With Cecal Colon Adenocarcinoma
Now Viewing
EP: 9.FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC
EP: 10.Monitoring and AE Management Strategies with Fruquintinib in CRC
EP: 11.Toxicity Considerations and Treatment Decisions in CRC
EP: 12.Multidisciplinary Care for Patients with CRC
EP: 13.Unmet Needs and Future Perspectives in Colorectal Cancer
Related Videos
Related Content
